EXAS vs STRO · rev $2.76B vs rev $62.0M
EXACT Sciences Corporation (EXAS) versus Sutro Biopharma (STRO) — a side-by-side from cached financials, not a winner call.
EXACT Sciences Corporation (EXAS) is a diagnostics & research company listed on NASDAQ.
Sutro Biopharma (STRO) is a biotechnology company listed on NASDAQ.
Latest reported EXAS revenue for 2024-12-31 was $2.76B. Net income was -$1.03B. Revenue was up 10.4% from 2023-12-31 to 2024-12-31. EXAS currently screens at market cap $20.03B.
Latest reported STRO revenue for 2024-12-31 was $62.0M. Net income was -$227.5M. Revenue was down 59.6% from 2023-12-31 to 2024-12-31. STRO currently screens at market cap $470.8M.
EXAS currently screens at market cap $20.03B. STRO currently screens at market cap $470.8M.
Not investment advice. Open the EXAS and STRO stock pages for the full models.
Not investment advice.